The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity (Q38905573)

7 September 2017

title

The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity (English)

1 reference

7 September 2017

Dario Neri

2

0 references

author name string

Christian Hess

series ordinal

1

1 reference

7 September 2017

publication date

27 February 2015

1 reference

Cancer Immunology, Immunotherapy

7 September 2017

published in

1 reference

7 September 2017

volume

64

1 reference

7 September 2017

issue

5

1 reference

7 September 2017

page(s)

635-644

1 reference

IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Preparation of phage antibodies to the ED-A domain of human fibronectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Immunocytokines: a novel class of potent armed antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Antibody targeted drugs as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Antibody-cytokine fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

The role of IL-13 and its receptor in allergy and inflammatory responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Differential regulation of IL-13 and IL-4 production by human CD8+ and CD4+ Th0, Th1 and Th2 T cell clones and EBV-transformed B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

"Diabodies": small bivalent and bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Emerging classes of armed antibody therapeutics against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Antibody-Based Delivery of IL2 and Cytotoxics Eradicates Tumors in Immunocompetent Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1666-8

10.1007/S00262-015-1666-8

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1045401193

0 references

1 reference